Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618286 | 0.94 | DNM1 (0.38) | PTPN11LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL4451535 | 0.92 | DNM1 (0.41) | PTPN11LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL14869442 | 0.90 | LMNA (0.41) | PTPN11LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL14869560 | 0.89 | CRHR1 (0.39) | PTPN11LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL14869506 | 0.87 | CA1 (0.40) | LMNAPKMSMN1; SMN2TLR8TLR7 | |
| SCHEMBL14869532 | 0.85 | LMNA (0.39) | PTPN11LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL14869413 | 0.84 | PTPN11 (0.36) | PTPN11LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL16450380 | 0.84 | KDM4E (0.40) | PTPN11LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13873109 | 0.84 | HRH3 (0.39) | LMNASMN1; SMN2HRH3ALDH1A1CASP1 | |
| SCHEMBL14869444 | 0.83 | HSP90AA1 (0.37) | PTPN11LMNAPKMSMN1; SMN2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20090324983-A1 | COMPOSITION AND PROCESS FOR COATING METAL SURFACES | HENKEL AG & CO. KGAA (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-0243120-B1 | TOUGH FLEXIBLE POLYMER BLENDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5003004-A | Star Polymers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0243120-A2 | Tough flexible polymer blends | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | PTPN11 575/4885LMNA 2331/4885PKM 280/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | PTPN11 575/4885LMNA 2331/4885PKM 280/4885 |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | PTPN11 625/4885LMNA 2222/4885PKM 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.